19 results
Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Thumbnail

- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience

Thumbnail

- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study

Thumbnail

- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report

Thumbnail

- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry

Thumbnail

- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma

Thumbnail

D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Thumbnail

- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs

Thumbnail

- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life

Thumbnail

- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab

Thumbnail

- D3.99 - Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics